The health-technology sector in London has seen a significant consolidation as a new venture moves to integrate clinical longevity expertise with advanced hardware engineering. Temple, a health-technology startup founded by Deepinder Goyal, has officially announced the acquisition of Longevous. This London-based medical practice has established a reputation for its focus on evidence-based longevity medicine, a field that seeks to apply scientific rigour to the pursuit of extended healthspans. The acquisition, formally announced on August 27, 2026, represents a strategic move to combine clinical expertise with the development of sophisticated health monitoring tools.
Leadership and Scientific Integration
As part of the integration, the founders of Longevous will take on senior leadership roles within Temple. Dr Robert Mohr, a board-certified physician with nearly two decades of clinical experience in emergency and precision medicine, has been appointed as the Chief Medical Officer. Joining him is Dr Avi Roy, an Oxford-trained biomedical scientist and former research fellow at the University of Oxford’s Centre for the Advancement of Sustainable Medical Innovation. Dr Roy will assume the role of Head of Science, where he will lead research efforts and ensure that the company’s innovations are grounded in robust scientific principles.
Advanced Wearable Technology
The primary focus of this acquisition is the enhancement of an experimental wearable device, also named Temple. This compact hardware is designed to be worn on the side of the head, positioned between the forehead and the ear. Unlike many consumer health trackers, this device is engineered to perform medical tracking of cerebral blood flow and oxygenation levels in real-time. By monitoring these specific physiological markers, the technology aims to provide insights into brain and cognitive health, offering users a continuous stream of data regarding their neurological well-being. The development of such a device requires a high degree of precision, as the sensors must accurately capture subtle changes in blood flow and oxygen levels within the cranium.
Validation and Evidence-Based Medicine
The integration of the Longevous team is intended to bolster the validation process for this new technology. The clinical experts from Longevous will work alongside the in-house science team at Temple to ensure that all claims made regarding the device are supported by rigorous evidence. This commitment to evidence-based medicine is central to the company’s mission. The acquisition follows a period of intensive internal testing, during which Dr Mohr and Dr Roy utilised the Temple device as daily users for two months. This period allowed the founders to subject the technology to significant scientific scrutiny and to review initial manuscripts related to its performance and potential applications.
Strategic Rationale and Future Outlook
The strategic rationale behind the deal lies in the synergy between Temple’s engineering capabilities and Longevous’s clinical insights. By bringing medical practitioners and scientists into the core leadership, Temple aims to bridge the gap between consumer technology and medical-grade health monitoring. The Longevous team’s involvement ensures that the wearable’s development is informed by real-world clinical experience and scientific research, which is critical for a device focusing on brain health. This collaborative approach is designed to ensure that the technology functions as intended and provides meaningful data for its users.
Despite the change in ownership, the published outcome states that Longevous will continue to operate as a distinct part of the Temple organisation. The clinic will maintain its existing client relationships, ensuring continuity of care for those currently receiving longevity medicine services. The acquisition strengthens Temple’s overall position in the competitive health-tech and longevity sectors as it moves toward a planned launch of its wearable technology. While the acquisition is a major milestone, the financial terms of the transaction remain undisclosed. Officials said that the deal is focused on the long-term integration of expertise rather than short-term financial metrics. As Temple prepares for its launch, the focus remains on the final stages of development and the rigorous validation of its cerebral monitoring capabilities.
